Abstract

BackgroundTrofile® is the prospectively validated HIV-1 tropism assay. Its use is limited by high costs, long turn-around time, and inability to test patients with very low or undetectable viremia. We aimed at assessing the efficiency of population genotypic assays based on gp120 V3-loop sequencing for the determination of tropism in plasma viral RNA and in whole-blood viral DNA. Contemporary and follow-up plasma and whole-blood samples from patients undergoing tropism testing via the enhanced sensitivity Trofile® (ESTA) were collected. Clinical and clonal geno2pheno[coreceptor] (G2P) models at 10% and at optimised 5.7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC).ResultsBoth clinical and clonal G2P (with different false positive rates) showed good performances in predicting the ESTA outcome (for V3 RNA-based clinical G2P at 10% false positive rate AUROC = 0.83, sensitivity = 90%, specificity = 75%). The rate of agreement between DNA- and RNA-based clinical G2P was fair (kappa = 0.74, p < 0.0001), and DNA-based clinical G2P accurately predicted the plasma ESTA (AUROC = 0.86). Significant differences in the viral populations were detected when comparing inter/intra patient diversity of viral DNA with RNA sequences.ConclusionsPlasma HIV RNA or whole-blood HIV DNA V3-loop sequencing interpreted with clinical G2P is cheap and can be a good surrogate for ESTA. Although there may be differences among viral RNA and DNA populations in the same host, DNA-based G2P may be used as an indication of viral tropism in patients with undetectable plasma viremia.

Highlights

  • Trofile® is the prospectively validated HIV-1 tropism assay

  • Given that most of the determinants of viral co-receptor tropism are based on polymorphisms of the third hypervariable region (V3) of the gp120, an alternative to the phenotypic approach is the usage of machine learning tools based on viral genotypic information

  • A study comparing the predictive performance of geno2pheno[coreceptor], position specific scoring matrices (PSSM) [12] and other methods against the first-generation Trofile® assay, concluded that current default implementations of co-receptor prediction algorithms were inadequate for predicting CXCR4 co-receptor usage in clinical samples, due to inability to detect low-level X4 virus [22]

Read more

Summary

Introduction

Trofile® is the prospectively validated HIV-1 tropism assay. Its use is limited by high costs, long turnaround time, and inability to test patients with very low or undetectable viremia. Several prediction models have been studied, from the first simple rule based on the polymorphisms at V3 codons 11 and 25, to the position specific scoring matrices (PSSM), neural networks, support vector machines, random forests and logistic models [10,11,12,13,14,15,16,17,18,19,20] Some of these studies identified additional factors possibly impacting viral tropism, such as viral subtype and CD4 cell counts [14,16,20]. A study comparing the predictive performance of geno2pheno[coreceptor], PSSM [12] and other methods against the first-generation Trofile® assay, concluded that current default implementations of co-receptor prediction algorithms were inadequate for predicting CXCR4 co-receptor usage in clinical samples, due to inability to detect low-level X4 virus [22]. Variable performance of in-silico models was shown when considering non-B HIV-1 variants [24,25,26]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call